United Therapeutics Corporation · NASDAQ:UTHR
United Therapeutics — J.P. Morgan Healthcare Conference 2025
20 slides from United Therapeutics's conference presentation, Jan 13, 2025
Slide 1: United Therapeutics: Enabling Inspiration
United Therapeutics: Enabling Inspiration J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025
Slide 2: Safe Harbor Statement
INTRODUCTION 2 2 Safe Harbor Statement All statements in this presentation are made as of January 13, 2025. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are
Slide 3: Enabling Inspiration
WHO WE ARE 3 3 Enabling Inspiration Founded to save a daughter’s life Structured as a Public Benefit Corporation OUR FOCUS Rare Lung Pediatric Organs & Diseases Oncology Organ Alternatives
Slide 4: Three Waves of Growth…
WHO WE ARE 4 4 Three Waves of Growth… Revenue1 REVOLUTION $16B Address the shortage of organs for transplant INNOVATION A cascade of clinical and regulatory events $8B over the next three years with the potential to expand our current business $4B FOUNDATION $3B A robust, cash generating commercial
Slide 5: …Leading to a Cascade of Clinical & Regulatory Events
WHO WE ARE 5 5 …Leading to a Cascade of Clinical & Regulatory Events9 2025 UKidney™ IND1 clearance CLES2 PMA3 approval TETON 2 data in IPF4 UKidney™ Study FPFT5 miroliverELAP6 data in acute liver failure ADVANCE OUTCOMES study close in PAH 2026 TETON 1 data in IPF Nebulized Tyvaso® sNDA7 for IPF ADV
Slide 6: A Solid Financial Foundation
FOUNDATION 6 6 A Solid Financial Foundation TRACK RECORD OF GROWTH DISCIPLINED FINANCIAL MANAGEMENT Nine consecutive quarters of $1 billion+ in annual operating cash flow3 double-digit y/y1 quarterly revenue Rigid budget algorithm: ≤50% of prior year growth revenue is spent on cash opex4 Three years
Slide 7: Market Leadership with a Robust Platform Approach
FOUNDATION 7 7 Market Leadership with a Robust Platform Approach INHALED The most prescribed prostacyclin in the U.S. ORAL 11 sequential quarters of y/y quarterly revenue growth PARENTERAL The most prescribed parenteral prostacyclin in the U.S.
Slide 8: Leading with Innovation
INNOVATION 8 8 Leading with Innovation A RELENTLESS PURSUIT OF INNOVATION OUR LONG-TERM VISION Durable, strong cash flow from our current portfolio Tyvaso® IPF + Innovative research to create a sustainable business Ralinepag PAH
Slide 9: TETON Program in IPF
INNOVATION 9 9 TETON Program in IPF SIR JOHN R. VANE FRS NOBEL LAUREATE TREPROSTINIL PIONEER Sir John Robert Vane. Photograph. Wellcome Collection. Source: Wellcome Collection.
Slide 10: TETON Program in IPF: Treprostinil Mechanisms of Action
INNOVATION 10 10 TETON Program in IPF TREPROSTINIL MECHANISMS OF ACTION Platelet Antiproliferation Vasodilation Inotropism Deaggregation CLINICAL DATA STARTING 2H/25 Sir John Robert Vane. Photograph. Wellcome Collection. Source: Wellcome Collection.
Slide 11: Ralinepag Could Be the First Once-Daily Prostacyclin
INNOVATION 11 11 Ralinepag Could Be the First Once-Daily Prostacyclin CONTINUOUS EVOLUTION OF PROSTACYCLIN DOSING CONVENIENCE TRIAL COMPLETE IN 2025; DATA EXPECTED IN 20269 1. QID = four times daily. 2. TID = three times daily. 3. BID = two times daily. 4. QD = once daily. 5. SQ = subcutaneous. 6. I
Slide 12: Four Platforms with Four Organs & Organ Alternatives
REVOLUTION 12 12 Four Platforms with Four Organs & Organ Alternatives BIO-ARTIFICIAL ORGAN ALTERNATIVES IVIVA Kidney mirokidney® miroliver® miroliverELAP®1 XENOTRANSPLANTATION UKidney™ UThymoKidney™ UHeart™ REGENERATIVE MEDICINE ULobe™ 3D AUTOLOGOUS PRINTING 1. ELAP = external liver assist product.
Slide 13: Rapidly Progressing Toward a Revolution
REVOLUTION 13 13 Rapidly Progressing Toward a Revolution UKIDNEY™ PRECLINICAL DATA RECENT NYU UKIDNEY™ TRANSPLANT Transplant completed November 25, 2024 Initial discharge December 6, 2024 NHP1 studies Interim NHP Xeno review Recipient doing well complete data available2 paper published3 Three UKidne
Slide 14: Pictured, left to right: Mr. Willie Bennett, Mrs. Towana Looney, Martine Rothblatt, Bina Rothblatt.
14 14 Pictured, left to right: Mr. Willie Bennett, Mrs. Towana Looney, Martine Rothblatt, Bina Rothblatt.
Slide 15: Rapidly Progressing Toward a Revolution
REVOLUTION 15 15 Rapidly Progressing Toward a Revolution
Slide 16: 16
16 16
Slide 17: 17
17 17
Slide 18: 18
18 18
Slide 19: Uniquely Positioned to Help Patients and Create Lasting Shareholder Value
REVOLUTION 19 19 Uniquely Positioned to Help Patients and Create Lasting Shareholder Value PBC PHILOSOPHY When our patients succeed, we all succeed CASH FLOW + INNOVATION A unique combination of strong cash flow and a revolutionary pipeline 36 MONTHS OF CATALYSTS A three-year cascade of potential cl
Slide 20: Ics
Ics A PUBLIC BENEFIT CORPORATION Uni t=) 3 3a wo ® = a
United Therapeutics — J.P. Morgan Healthcare Conference 2025 on 6ix